Cargando…

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma

Cytokine-induced killer cells (CIK) in combination with dendritic cells (DCs) have shown favorable outcomes in renal cell carcinoma (RCC), yet some patients exhibit recurrence or no response to this therapy. In a broader perspective, enhancing the antitumor response of DC-CIK cells may help to addre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ying, Wu, Xiaolong, Sharma, Amit, Weiher, Hans, Schmid, Matthias, Kristiansen, Glen, Schmidt-Wolf, Ingo G. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453234/ https://www.ncbi.nlm.nih.gov/pubmed/36091050 http://dx.doi.org/10.3389/fimmu.2022.925633

Ejemplares similares

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials
por: Zhang, Ying, et al.
Publicado: (2021)

30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective
por: Sharma, Amit, et al.
Publicado: (2021)

Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism
por: Zhou, Liang, et al.
Publicado: (2022)

Comparative investigation of the effects of specific antigen-sensitized DC-CIK and DC-CTL cells against B16 melanoma tumor cells
por: Ren, Peng-Tao, et al.
Publicado: (2017)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer
por: Liu, Guiyuan, et al.
Publicado: (2022)

Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics
por: Zhang, Ying, et al.
Publicado: (2020)

Combination treatment of pembrolizumab with DC-CIK cell therapy for advanced hepatocellular carcinoma: A case report
por: Huang, Shao M., et al.
Publicado: (2023)

The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials
por: Xiao, Zheng, et al.
Publicado: (2018)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

Killing effects of Huaier Granule combined with DC-CIK on nude mice transplanted with colon carcinoma cell line
por: Sun, Wen-Wen, et al.
Publicado: (2017)

A Low Dose of Pure Cannabidiol Is Sufficient to Stimulate the Cytotoxic Function of CIK Cells without Exerting the Downstream Mediators in Pancreatic Cancer Cells
por: Garofano, Francesca, et al.
Publicado: (2022)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro
por: Zhao, Qun, et al.
Publicado: (2010)

Stimulation of DC-CIK with PADI4 Protein Can Significantly Elevate the Therapeutic Efficiency in Esophageal Cancer
por: Liu, Chunyan, et al.
Publicado: (2019)

Case Report: Chemotherapy and Radiotherapy Combined With DC-CIK for Pulmonary and Mediastinal Metastases From Nasopharyngeal Carcinoma
por: Gan, Yi-Xiu, et al.
Publicado: (2022)

IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
por: Qu, Qiuxia, et al.
Publicado: (2020)

NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation
por: Wu, Xiaolong, et al.
Publicado: (2021)

Innovative Clinical Perspectives for CIK Cells in Cancer Patients
por: Introna, Martino, et al.
Publicado: (2018)

Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
por: Witt, Kristina, et al.
Publicado: (2021)

A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines
por: Li, Yutao, et al.
Publicado: (2022)

DC-CIK biotherapy for a recurrent benign lymphoepithelial lesion of the salivary gland: A case report and literature review
por: XING, DEJUN, et al.
Publicado: (2014)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
por: Song, Meng‐Jia, et al.
Publicado: (2021)

Cereus jamacaru D.C. Hydroalcoholic Extract Promotes Anti-Cytotoxic and Antitumor Activity
por: Vencioneck Dutra, Jean Carlos, et al.
Publicado: (2018)

Antitumor effect of plant-produced anti-CTLA-4 monoclonal antibody in a murine model of colon cancer
por: Bulaon, Christine Joy I., et al.
Publicado: (2023)

The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors
por: Wang, Ying, et al.
Publicado: (2015)

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST
por: Fiorino, Erika, et al.
Publicado: (2022)

Effect of chaetocin on renal cell carcinoma cells and cytokine-induced killer cells
por: Rombo, Roman, et al.
Publicado: (2016)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines
por: Ceglia, Valentina, et al.
Publicado: (2022)

Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy
por: Zhang, Yajing, et al.
Publicado: (2013)

Radiation Dose Escalation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance Local and Distant Antitumor Effect in Murine Osteosarcoma
por: Takenaka, Wataru, et al.
Publicado: (2020)

Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma
por: Esser, Laura, et al.
Publicado: (2016)

CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response
por: Charpentier, Maud, et al.
Publicado: (2023)

Cytokine-induced killer (CIK) cells: from basic research to clinical translation
por: Guo, Yelei, et al.
Publicado: (2015)

Comparative Proteomic Analysis of Lysine Acetylation in Fish CIK Cells Infected with Aquareovirus
por: Guo, Hong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fu4r5al25chfmr8in9tdb6da2k